India's Biotech Inflection Point: A Pre-Seed Investor's Perspective
- Ahammad Shibil
- 4 hours ago
- 9 min read
India's bioeconomy just crossed $165 billion. A decade ago, it was $10 billion.
That's a 16x expansion in ten years, and we're only getting started.
At Speciale, we've been investing in Indian deep science since 2018 — across three funds, 35+ companies, and sectors ranging from space and semiconductors to defence and AI. Over the past two years, biotech has become one of the most exciting areas in our portfolio. It is also one of the most misunderstood by the broader investor community.
This is our attempt to change that.
Two Curves, One Moment
To understand why India's biotech moment is happening now, you need to hold two ideas at once.
The first: biology is getting cheaper to do. The cost of DNA sequencing has collapsed faster than Moore's Law — from $100 million per genome in 2001 to under $200 today. Gene synthesis costs have dropped by orders of magnitude. AI tools like AlphaFold have compressed years of protein structure research into hours. The entire stack of tools required to do serious biology — once the exclusive domain of well-funded Western research institutions — is now accessible to a PhD in Bangalore.
The second: biology is getting more valuable to own. The era of small-molecule drugs is plateauing. The frontier has shifted to biologics, cell therapies, gene therapies, and AI-designed molecules — modalities where the IP is harder to copy, the barriers to entry are higher, and acquirer appetite is enormous. Global pharma operates more like a venture capital firm than a manufacturer today — actively seeking early-stage platforms, writing licensing checks, and acquiring discovery assets before Phase II. Sun Pharma paid $416 million for Checkpoint Therapeutics. Novo Holdings put $47.5 million into MedGenome's Series E. Eli Lilly partnered with a16z to deploy $500 million specifically to find the next generation of biotech platforms.
India sits at the exact intersection of these two curves. The cost of doing biology here is 40–60% lower than in the West at genuinely comparable quality. And for the first time, the ambition — supported by policy, capital, and a generation of founders who have seen what's possible — is pointed at ownership, not service.
That intersection is where we invest.
India Already Knew How to Do This
In 1978, Kiran Mazumdar-Shaw started Biocon in the garage of her rented house in Bangalore with ₹10,000 and a brewer's instinct for fermentation. The company began by producing industrial enzymes — pectinase from papaya, used in food processing and beverages. By 1979, Biocon was the first Indian company to export enzymes to the US and Europe. Over the next four decades, it became India's largest biopharmaceutical company, pioneering the world's first Pichia-based recombinant human insulin and proving, definitively, that Indian science could build products that compete globally.
The proof was always there.
And then the world spent the next three decades convincing Indian biology to forget that lesson.
Global pharma came in with CRO contracts, CDMO agreements, and GCC setups. Good money, reliable work, world-class exposure. Thousands of brilliant Indian scientists found themselves running experiments designed in Boston, writing reports read in Basel, supporting pipelines owned in San Francisco. India became, in the language of the industry, a service economy for biology. Excellent at execution. Absent from ownership.
We don't say this as criticism. The infrastructure was young, the regulatory pathways unclear, and building a product company in biology is genuinely hard. The services path was rational for a long time.
But the underlying logic has changed. The infrastructure that took Biocon 45 years to help build is now available to a first-time founder from IISc or CCMB. The regulatory environment is evolving. The capital — domestic and international — is arriving. And for the first time, government policy is explicitly aligned with product ownership rather than service delivery.
The BioE3 Policy, approved by the Union Cabinet in August 2024, placed biomanufacturing at the centre of India's industrial strategy. BIRAC has received ₹2,000 crore under the new national RDI Fund to deploy into biotech startups — the first call for proposals opened in February 2026. The Union Budget added ₹10,000 crore under Biopharma SHAKTI for domestic biologics. These aren't marginal interventions. They are a structural statement: India is done being the world's biology back-office.
Three Moats Being Built in Real Time
We think about India's biotech opportunity through three distinct moats. Each has a different source of competitive advantage. Together, they make the case that India's role in global biotech is not about being cheaper — it's about being better positioned to own the future of biology.
Moat One: Bio-AI — Data Sovereignty as Competitive Advantage
The global conversation about AI in drug discovery focuses on compute and model architecture. India's advantage is different — and more durable: biological data at scale, rooted in a population the rest of the world has chronically underserved.
India has 1.4 billion people with a genomic and clinical profile deeply underrepresented in Western biomedical datasets. The diseases that global pharma has treated as secondary markets — diabetes affecting over 100 million Indians, tuberculosis still endemic, rare genetic disorders prevalent in a population that has barely been sequenced — are India's primary reality. The data that comes from seriously studying this biology does not exist elsewhere. It cannot be bought, scraped, or approximated. It has to be generated here, by researchers embedded here, over the years.
The companies that build proprietary biological datasets from this population and train predictive models on top of them will have a moat that no amount of compute can replicate. When the world's largest pharma companies realise they have systematically underrepresented nearly a fifth of humanity in their discovery pipelines — and that the companies that fixed that problem are based in Bangalore — the licensing conversations will be one-sided.
Peptris Technologies demonstrates what this looks like in practice. Founded in Bangalore in 2019, the team built AI models that predict drug-target interactions, enabling rapid in-silico screening of millions of compounds. In March 2025, they out-licensed PEPR124 — India's first AI-discovered drug candidate, targeting Duchenne Muscular Dystrophy — to US-based Revio Therapeutics. Peptris retains commercialisation rights in BRICS markets; Revio takes global markets. The deal closed before a Series A. It didn't happen because Peptris was cheap. It happened because the platform works, the models are theirs, and a US biotech recognised that licensing this capability was faster than building it internally.
That is what data sovereignty looks like in practice. Bio-AI in India is not a cost story. It is a platform ownership story.
Moat Two: Cell and Gene Therapy — Resetting the Global Price Point
CAR-T therapy costs between $370,000 and $530,000 per patient in the United States. ImmunoACT's NexCAR19 — India's first approved CAR-T, developed at IIT Bombay — is priced at roughly $40,000–$50,000. Roughly one-tenth the cost, with clinical efficacy data showing a 70% overall response rate across 53 evaluable patients. That is not a rounding error. That is a fundamentally different product for a fundamentally different global reality.
The significance is easy to miss if you read it only as a local market story. It isn't. The question for advanced cell and gene therapies globally is not whether the science works — it does. The question is whether these therapies will ever reach the billion people outside the US and Europe who need them. At $400,000+ per patient, the answer is effectively no. At $40,000–$50,000, the conversation changes completely.
India's CGT cost advantage is not primarily about labour. It is about the entire stack — local vector manufacturing capabilities being built now, clinical infrastructure shaped around large patient populations, regulatory pathways being calibrated in real time, and a manufacturing ecosystem being purpose-built. The India-specific CGT manufacturing buildout is already underway: Bharat Biotech's dedicated CGT facility at Genome Valley, Intas's first Indian CGT manufacturing centre, Aurigene's viral vector CDMO — representing over $115 million in committed infrastructure in the last two years alone.
What India is building in CGT is not a cheaper version of what the West built. It is a different architecture entirely — designed to serve a global patient population that the current system cannot reach. The companies that own the platforms and the clinical data from that architecture will hold a structural advantage when global pharma looks for partners on next-generation CGT programs. And they will look.
Moat Three: Synthetic Biology — Industrial Depth as Strategic Infrastructure
India's industrial biotech sector — bioethanol, enzymes, fermentation — contributed nearly half of the $165 billion bioeconomy in 2024, representing roughly $78 billion in value. This is not just a legacy industry. It is a manufacturing infrastructure built over decades that synthetic biology startups can now inherit and upgrade.
The ability to engineer microorganisms to produce chemicals, materials, and proteins from renewable feedstocks is one of the most significant platform opportunities of the next decade. It sits at the intersection of climate, manufacturing, and food security — sectors where both policy urgency and commercial demand are accelerating. The BioE3 Policy has made biomanufacturing a national priority, with 21 advanced bio-enabler facilities being established across the country.
Fermbox Bio is one of the clearest examples of this thesis in motion. Founded in Bangalore in 2022 using precision fermentation and engineered microbial strains, Fermbox converts renewable feedstocks into high-value bio-based chemicals and materials. Their first commercial product, EN3ZYME — a cellulosic enzyme cocktail for the conversion of agricultural waste into fermentable sugars for 2G ethanol production — is already in the market. The company has raised $2.5 million and entered a joint venture with Thailand's BBGI (Bio-Based Green Innovation) to establish a precision fermentation CDMO facility in the Eastern Economic Corridor — with a total planned investment of $82 million across three phases and capacity targeting up to 1 million litres of fermentation. The joint venture is designed to serve global customers across enzymes, speciality chemicals, and sustainable materials.
What makes this defensible is not the individual products. It is the platform — and the manufacturing relationships built on top of India's decades of industrial fermentation expertise.
How We Think About Investing in This Space
Biotech is not like software. The cycles are longer, the failure modes are more expensive, and the diligence required before writing a check is categorically different. Most early-stage generalist investors avoid it for exactly these reasons. We have leaned in — and developed a specific point of view on what actually matters at the pre-seed stage.
We do the science ourselves. Before writing a check in biotech, we build independent conviction on the science — through our own reading and analysis, through external scientific advisors, and through peer networks of the founders themselves. We are not looking for someone to tell us the science is credible. We are forming our own view, which means our conviction is real when we have it.
We are patient in ways that most early-stage investors are not. A biotech investment at pre-seed has a fundamentally different time horizon than a SaaS investment. The founders need to know that their lead investor understands this and will not panic when the first milestone takes eighteen months instead of twelve. Our fund structure is built for this holding period.
We bring the network that matters for biotech exits. The exit pathways in biotech run through global pharma partnerships, licensing deals, and strategic acquisitions. We have spent years building relationships across this landscape — with business development teams at companies that execute these deals, with the late-stage investors who participate in biotech rounds, and with advisors who help companies navigate the regulatory and commercial milestones that precede an exit. When a Speciale portfolio company is ready for those conversations, we are already in the room.
The Capital Stack Is Maturing
The investment environment supporting this thesis has changed materially.
India's PE-VC market deployed $43 billion in 2024, with healthcare deal volumes rising 80% year-on-year. Of those exits, 68% came through IPOs — a record. M&A deal value in the first half of 2025 alone already surpassed all of 2024. Temasek backed Molbio Diagnostics to a $1.6 billion unicorn valuation. Novo Holdings invested in MedGenome. The late-stage signal is unambiguous.
At the early stage, the infrastructure is being built in real time. BIRAC received ₹2,000 crore under the new national RDI Fund — its first call for proposals opened in February 2026, targeting biotech startups at Technology Readiness Level 4 and above. The Union Budget added ₹10,000 crore under Biopharma SHAKTI for domestic biologics. BYT Capital, a dedicated Indian life sciences fund, launched in 2025.
The weakest link remains the Series A. Too many companies with validated science and early commercial traction stall between proof-of-concept and clinical validation because the Indian Series A ecosystem for biotech is still nascent. This will change — the late-stage signal is too strong for it not to. But for now, the founders who can design their early milestones to be fundable by international capital, or to generate licensing revenue before needing a large clinical round, have a meaningful structural advantage.
The Question Is Ambition
India took 45 years to build Biocon. The next generation of companies — building on the infrastructure that Biocon and its peers created, with access to AI tools that compress discovery timelines, manufacturing capabilities being purpose-built, and a policy environment explicitly designed to support product ownership — will not take nearly that long.
What they need is not permission. The ecosystem is ready, the capital is arriving, and the exits are being demonstrated. What they need is the ambition to build products rather than services — to own the IP, take the risk, and capture the value when the science works.
At Speciale, we write the first institutional check — typically Rs. 4–10 crore at pre-seed — into the founders who have made that choice. We do it because we believe the intersection of India's biological talent, its cost structure, and its newly aligned policy environment creates a window for building companies of global consequence.
We are not passive observers of this transition. We intend to be among its architects.
If you are a founder building at the intersection of biology, AI, and manufacturing — we want to talk.
If you are an investor looking for exposure to Indian biotech at the earliest stage, so do we.
